

AVEO PHARMACEUTICALS INC  
Form SC 13G  
February 09, 2012

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**SCHEDULE 13G**

Under the Securities Exchange Act of 1934

(Amendment No. )\*

**AVEO PHARMACEUTICALS, INC.**

(Name of issuer)

**Common Stock**  
(Title of class of securities)

**53588109**  
(CUSIP number)

**December 31, 2011**  
(Date of event which requires filing of this statement)

Edgar Filing: AVEO PHARMACEUTICALS INC - Form SC 13G

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13G

CUSIP No. 53588109

Page 2 of 18 Pages

(1) Names of reporting persons

MPM BioVentures II, L.P.

(2) Check the appropriate box if a member of a group (see instructions)

(a)  (b)

(3) SEC use only

(4) Citizenship or place of organization

Delaware

(5) Sole voting power

Number of

shares 164,567  
(6) Shared voting power

beneficially

owned by 0  
each (7) Sole dispositive power

reporting

person 164,567  
(8) Shared dispositive power

with:

0

(9) Aggregate amount beneficially owned by each reporting person

164,567

(10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)

Edgar Filing: AVEO PHARMACEUTICALS INC - Form SC 13G

(11) Percent of class represented by amount in Row (9)

0.4%

(12) Type of reporting person (see instructions)

PN

SCHEDULE 13G

CUSIP No. 53588109

Page 3 of 18 Pages

(1) Names of reporting persons

MPM BioVentures II-QP, L.P.

(2) Check the appropriate box if a member of a group (see instructions)

(a)  (b)

(3) SEC use only

(4) Citizenship or place of organization

Delaware

(5) Sole voting power

Number of

shares 1,493,260  
(6) Shared voting power

beneficially

owned by 0  
each (7) Sole dispositive power

reporting

person 1,493,260  
(8) Shared dispositive power

with:

0

(9) Aggregate amount beneficially owned by each reporting person

1,493,260

(10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)

Edgar Filing: AVEO PHARMACEUTICALS INC - Form SC 13G

(11) Percent of class represented by amount in Row (9)

3.5%

(12) Type of reporting person (see instructions)

PN

SCHEDULE 13G

CUSIP No. 53588109

Page 4 of 18 Pages

(1) Names of reporting persons

MPM BioVentures GmbH & Co. Parallel-Beteiligungs KG

(2) Check the appropriate box if a member of a group (see instructions)

(a)  (b)

(3) SEC use only

(4) Citizenship or place of organization

Germany

(5) Sole voting power

Number of

shares 525,732  
(6) Shared voting power

beneficially

owned by 0  
each (7) Sole dispositive power

reporting

person 525,732  
(8) Shared dispositive power

with:

0

(9) Aggregate amount beneficially owned by each reporting person

525,732

(10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)

Edgar Filing: AVEO PHARMACEUTICALS INC - Form SC 13G

(11) Percent of class represented by amount in Row (9)

1.2%

(12) Type of reporting person (see instructions)

PN



SCHEDULE 13G

CUSIP No. 53588109

Page 5 of 18 Pages

(1) Names of reporting persons

MPM Asset Management Investors 2002 LLC

(2) Check the appropriate box if a member of a group (see instructions)

(a)  (b)

(3) SEC use only

(4) Citizenship or place of organization

Delaware

(5) Sole voting power

Number of

shares 25,402  
(6) Shared voting power

beneficially

owned by 0  
each (7) Sole dispositive power

reporting

person 25,402  
(8) Shared dispositive power

with:

0

(9) Aggregate amount beneficially owned by each reporting person

25,402

(10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)

Edgar Filing: AVEO PHARMACEUTICALS INC - Form SC 13G

(11) Percent of class represented by amount in Row (9)

0.1%

(12) Type of reporting person (see instructions)

OO

SCHEDULE 13G

CUSIP No. 53588109

Page 6 of 18 Pages

(1) Names of reporting persons

MPM Asset Management II, L.P.

(2) Check the appropriate box if a member of a group (see instructions)

(a)  (b)

(3) SEC use only

(4) Citizenship or place of organization

Delaware

(5) Sole voting power

Number of

shares 0  
(6) Shared voting power

beneficially

owned by 2,183,559\*  
each (7) Sole dispositive power

reporting

person 0  
(8) Shared dispositive power

with:

2,183,559\*  
(9) Aggregate amount beneficially owned by each reporting person

2,183,559\*  
(10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)

Edgar Filing: AVEO PHARMACEUTICALS INC - Form SC 13G

(11) Percent of class represented by amount in Row (9)

5.1%

(12) Type of reporting person (see instructions)

PN

\* The shares are held as follows: 1,493,260 by MPM BioVentures II-QP, L.P. ( BV II QP ); 164,567 by MPM BioVentures II, L.P. ( BV II ); and 525,732 by MPM BioVentures GmbH & Co. Parallel-Beteiligungs KG ( BV KG ). The Reporting Person is the direct general partner of BV II QP, BV II and BV KG.

SCHEDULE 13G

CUSIP No. 53588109

Page 7 of 18 Pages

(1) Names of reporting persons

MPM Asset Management II LLC

(2) Check the appropriate box if a member of a group (see instructions)

(a)  (b)

(3) SEC use only

(4) Citizenship or place of organization

Delaware

(5) Sole voting power

Number of

shares 0  
(6) Shared voting power

beneficially

owned by 2,183,559\*  
each (7) Sole dispositive power

reporting

person 0  
(8) Shared dispositive power

with:

2,183,559\*  
(9) Aggregate amount beneficially owned by each reporting person

2,183,559\*  
(10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)

Edgar Filing: AVEO PHARMACEUTICALS INC - Form SC 13G

(11) Percent of class represented by amount in Row (9)

5.1%

(12) Type of reporting person (see instructions)

OO

\* The shares are held as follows: 1,493,260 by BV II QP; 164,567 by BV II; and 525,732 by BV KG. The Reporting Person is the indirect general partner of BV II QP, BV II and BV KG.

SCHEDULE 13G

CUSIP No. 53588109

Page 8 of 18 Pages

(1) Names of reporting persons

Ansbert Gadicke

(2) Check the appropriate box if a member of a group (see instructions)

(a)  (b)

(3) SEC use only

(4) Citizenship or place of organization

United States

(5) Sole voting power

Number of

shares (6) 0  
Shared voting power

beneficially

owned by (7) 2,208,961\*  
each Sole dispositive power

reporting

person (8) 0  
Shared dispositive power

with:

(9) 2,208,961\*  
Aggregate amount beneficially owned by each reporting person

(10) 2,208,961\*  
Check if the aggregate amount in Row (9) excludes certain shares (see instructions)

Edgar Filing: AVEO PHARMACEUTICALS INC - Form SC 13G

(11) Percent of class represented by amount in Row (9)

5.1%

(12) Type of reporting person (see instructions)

IN

\* The shares are held as follows: 1,493,260 by BV II QP; 164,567 by BV II; 25,402 by MPM Asset Management Investors 2002 BVII LLC ( AM 2002 ); and 525,732 by BV KG. MPM Asset Management II, L.P. ( AM LP ) and MPM Asset Management II LLC ( AM II LLC ) are the direct and indirect general partners of BV II QP, BV II and BV KG. The Reporting Person is an investment manager of AM II LLC and AM 2002. The Reporting Person disclaims beneficial ownership of all such shares except to the extent of his proportionate pecuniary interests therein.



SCHEDULE 13G

CUSIP No. 53588109

Page 9 of 18 Pages

(1) Names of reporting persons

Luke Evin

(2) Check the appropriate box if a member of a group (see instructions)

(a)  (b)

(3) SEC use only

(4) Citizenship or place of organization

United States

(5) Sole voting power

Number of

shares (6) 0  
Shared voting power

beneficially

owned by (7) 2,208,961\*  
each Sole dispositive power

reporting

person (8) 0  
Shared dispositive power

with:

(9) 2,208,961\*  
Aggregate amount beneficially owned by each reporting person

(10) 2,208,961\*  
Check if the aggregate amount in Row (9) excludes certain shares (see instructions)

Edgar Filing: AVEO PHARMACEUTICALS INC - Form SC 13G

(11) Percent of class represented by amount in Row (9)

5.1%

(12) Type of reporting person (see instructions)

IN

\* The shares are held as follows: 1,493,260 by BV II QP; 164,567 by BV II; 25,402 by AM 2002; and 525,732 by BV KG. AM LP and AM II LLC are the direct and indirect general partners of BV II QP, BV II and BV KG. The Reporting Person is an investment manager of AM II LLC and AM 2002. The Reporting Person disclaims beneficial ownership of all such shares except to the extent of his proportionate pecuniary interests therein.

SCHEDULE 13G

CUSIP No. 53588109

Page 10 of 18 Pages

(1) Names of reporting persons

Nicholas Galakatos

(2) Check the appropriate box if a member of a group (see instructions)

(a)  (b)

(3) SEC use only

(4) Citizenship or place of organization

United States

(5) Sole voting power

Number of

shares 30,833\*  
(6) Shared voting power

beneficially

owned by 2,208,961\*\*  
each (7) Sole dispositive power

reporting

person 30,833\*  
(8) Shared dispositive power

with:

2,208,961\*\*

(9) Aggregate amount beneficially owned by each reporting person

2,239,794\*\*

(10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)

Edgar Filing: AVEO PHARMACEUTICALS INC - Form SC 13G

(11) Percent of class represented by amount in Row (9)

5.2%

(12) Type of reporting person (see instructions)

IN

\* Represents shares issuable pursuant to options exercisable within 60 days of December 31, 2011.

\*\* The shares are held as follows: 1,493,260 by BV II QP; 164,567 by BV II; 525,732 by BV KG; and 25,402 by AM 2002. AM LP and AM II LLC are the direct and indirect general partners of BV II QP, BV II and BV KG. The Reporting Person is an investment manager of AM II LLC and AM 2002. The Reporting Person disclaims beneficial ownership of all such shares except to the extent of his proportionate pecuniary interests therein.

SCHEDULE 13G

CUSIP No. 53588109

Page 11 of 18 Pages

(1) Names of reporting persons

Michael Steinmetz

(2) Check the appropriate box if a member of a group (see instructions)

(a)  (b)

(3) SEC use only

(4) Citizenship or place of organization

United States

(5) Sole voting power

Number of

shares (6) 0  
Shared voting power

beneficially

owned by (7) 2,208,961\*  
each Sole dispositive power

reporting

person (8) 0  
Shared dispositive power

with:

(9) 2,208,961\*  
Aggregate amount beneficially owned by each reporting person

(10) 2,208,961\*  
Check if the aggregate amount in Row (9) excludes certain shares (see instructions)

Edgar Filing: AVEO PHARMACEUTICALS INC - Form SC 13G

(11) Percent of class represented by amount in Row (9)

5.1%

(12) Type of reporting person (see instructions)

IN

\* The shares are held as follows: 1,493,260 by BV II QP; 164,567 by BV II; 525,732 by BV KG; and 25,402 by AM 2002. AM LP and AM II LLC are the direct and indirect general partners of BV II QP, BV II and BV KG. The Reporting Person is an investment manager of AM II LLC and AM 2002. The Reporting Person disclaims beneficial ownership of all such shares except to the extent of his proportionate pecuniary interests therein.

SCHEDULE 13G

CUSIP No. 53588109

Page 12 of 18 Pages

(1) Names of reporting persons

Kurt Wheeler

(2) Check the appropriate box if a member of a group (see instructions)

(a)  (b)

(3) SEC use only

(4) Citizenship or place of organization

United States

(5) Sole voting power

Number of

shares (6) 0  
Shared voting power

beneficially

owned by (7) 2,208,961\*  
each Sole dispositive power

reporting

person (8) 0  
Shared dispositive power

with:

(9) 2,208,961\*  
Aggregate amount beneficially owned by each reporting person

(10) 2,208,961\*  
Check if the aggregate amount in Row (9) excludes certain shares (see instructions)

Edgar Filing: AVEO PHARMACEUTICALS INC - Form SC 13G

(11) Percent of class represented by amount in Row (9)

5.1%

(12) Type of reporting person (see instructions)

IN

\* The shares are held as follows: 1,493,260 by BV II QP; 164,567 by BV II; 525,732 by BV KG; and 25,402 by AM 2002. AM LP and AM II LLC are the direct and indirect general partners of BV II QP, BV II and BV KG. The Reporting Person is an investment manager of AM II LLC and AM 2002. The Reporting Person disclaims beneficial ownership of all such shares except to the extent of his proportionate pecuniary interests therein.



**Item 1.**

(a) Name of Issuer

AVEO Pharmaceuticals, Inc.

(b) Address of Issuer's Principal Executive Offices

75 Sidney Street, 4<sup>th</sup> Floor

Cambridge, MA 02139

**Item 2.**

(a) Name of Person Filing

MPM BioVentures II, LP

MPM BioVentures II-QP, L.P.

MPM BioVentures GmbH & Co. Parallel-Beteiligungs KG

MPM Asset Management Investors 2002 BVII LLC

MPM Asset Management II, L.P.

MPM Asset Management II LLC

Ansbert Gadicke

Luke Evnin

Nicholas Galakatos

Michael Steinmetz

Kurt Wheeler

(b) Address of Principal Business Office or, if none, Residence

c/o MPM Capital L.P.

The John Hancock Tower

200 Clarendon Street, 54<sup>th</sup> Floor

Boston, MA 02116

(c) Citizenship

Edgar Filing: AVEO PHARMACEUTICALS INC - Form SC 13G

All entities were organized in Delaware except MPM BioVentures GmbH & Co. Parallel-Beteiligungs KG, which was organized in Germany. The individuals are all United States citizens.

(d) Title of Class of Securities

Common Stock

(e) CUSIP Number

53588109

**Item 3.** If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:  
Not applicable

**Item 4. Ownership**

(a) Amount Beneficially Owned:

	<b>September 30,</b>
MPM BioVentures II, L.P.	164,567
MPM BioVentures II-QP, L.P.	1,493,260
MPM BioVentures GmbH & Co. Parallel-Beteiligungs KG	525,732
MPM Asset Management Investors 2002 BVII LLC	25,402
MPM Asset Management II, L.P.	2,183,559(1)
MPM Asset Management II LLC	2,183,559(1)
Ansbert Gadicke	2,208,961(2)
Luke B. Evin	2,208,961(2)
Nicholas Galakatos	2,239,794(2)(3)
Michael Steinmetz	2,208,961(2)
Kurt Wheeler	2,208,961(2)
Percent of Class:	

	<b>September 30,</b>
MPM BioVentures II, L.P.	0.4%
MPM BioVentures II-QP, L.P.	3.5%
MPM BioVentures GmbH & Co. Parallel-Beteiligungs KG	1.2%
MPM Asset Management Investors 2002 BVII LLC	0.1%
MPM Asset Management II, L.P.	5.1%
MPM Asset Management II LLC	5.1%
Ansbert Gadicke	5.1%
Luke B. Evin	5.1%
Nicholas Galakatos	5.2%
Michael Steinmetz	5.1%
Kurt Wheeler	5.1%

(b) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote

	<b>September 30,</b>
MPM BioVentures II, L.P.	164,567
MPM BioVentures II-QP, L.P.	1,493,260
MPM BioVentures GmbH & Co. Parallel-Beteiligungs KG	525,732
MPM Asset Management Investors 2002 BVII LLC	25,402
MPM Asset Management II, L.P.	0
MPM Asset Management II LLC	0
Ansbert Gadicke	0

Edgar Filing: AVEO PHARMACEUTICALS INC - Form SC 13G

Luke B. Evin	0
Nicholas Galakatos	30,833(3)
Michael Steinmetz	0
Kurt Wheeler	0

## (ii) Shared power to vote or to direct the vote

	<b>September 30,</b>
MPM BioVentures II, L.P.	0
MPM BioVentures II-QP, L.P.	0
MPM BioVentures GmbH & Co. Parallel-Beteiligungs KG	0
MPM Asset Management Investors 2002 BVII LLC	0
MPM Asset Management II, L.P.	2,183,559(1)
MPM Asset Management II LLC	2,183,559(1)
Ansbert Gadicke	2,208,961(2)
Luke B. Evnin	2,208,961(2)
Nicholas Galakatos	2,208,961(2)
Michael Steinmetz	2,208,961(2)
Kurt Wheeler	2,208,961(2)

## (iii) Sole power to dispose or to direct the disposition of

	<b>September 30,</b>
MPM BioVentures II, LP	164,567
MPM BioVentures II-QP, L.P.	1,493,260
MPM BioVentures GmbH & Co. Parallel-Beteiligungs KG	525,732
MPM Asset Management Investors 2002 LLC	25,402
MPM Asset Management II, L.P.	0
MPM Asset Management II LLC	0
Ansbert Gadicke	0
Luke Evnin	0
Nicholas Galakatos	30,833(3)
Michael Steinmetz	0
Kurt Wheeler	0

## (iv) Shared power to dispose or to direct the disposition of

	<b>September 30,</b>
MPM BioVentures II, LP	0
MPM BioVentures II-QP, L.P.	0
MPM BioVentures GmbH & Co. Parallel-Beteiligungs KG	0
MPM Asset Management Investors 2002 BVII LLC	0
MPM Asset Management II, L.P.	2,183,559(1)
MPM Asset Management II LLC	2,183,559(1)
Ansbert Gadicke	2,208,961(2)
Luke B. Evnin	2,208,961(2)
Nicholas Galakatos	2,208,961(2)
Michael Steinmetz	2,208,961(2)
Kurt Wheeler	2,208,961(2)

## Edgar Filing: AVEO PHARMACEUTICALS INC - Form SC 13G

- (1) The shares are held as follows: 1,493,260 by BV II QP; 164,567 by BV II; and 525,732 by BV KG. AM LP and AM II LLC are the direct and indirect general partners of BV II QP, BV II and BV KG.
- (2) The shares are held as follows: 1,493,260 by BV II QP; 164,567 by BV II; 525,732 by BV KG; and 25,402 by AM 2002. AM LP and AM II LLC are the direct and indirect general partners of BV II QP, BV II and BV KG. The Reporting Person is an investment manager of AM II LLC and AM 2002.
- (3) Includes 30,833 shares issuable upon exercise of options within 60 days of December 31, 2011.

**Item 5. Ownership of Five Percent or Less of a Class**

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following "":

**Item 6. Ownership of More than Five Percent on Behalf of Another Person**

Not Applicable

**Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.**

Not Applicable

**Item 8. Identification and Classification of Members of the Group**

Not Applicable

**Item 9. Notice of Dissolution of a Group**

Not Applicable

**Item 10. Certification**

Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 8, 2012

MPM BIOVENTURES II, L.P.

By: MPM Asset Management II, L.P.,  
its General Partner

By: MPM Asset Management II LLC,  
its General Partner

By: /s/ Luke B. Evnin  
Name: Luke B. Evnin  
Title: Investment Manager

MPM BIOVENTURES GMBH & CO. PARALLEL-BETEILIGUNGS  
KG

By: MPM Asset Management II LP, in its capacity as the Special  
Limited Partner

By: MPM Asset Management II LLC, its General Partner

By: /s/ Luke B. Evnin  
Name: Luke B. Evnin  
Title: Investment Manager

MPM ASSET MANAGEMENT II L.P.

By: MPM Asset Management II LLC, its General Partner

By: /s/ Luke B. Evnin  
Name: Luke B. Evnin  
Title: Investment Manager

MPM BIOVENTURES II-QP, L.P.

By: MPM Asset Management II, L.P.,  
its General Partner

By: MPM Asset Management II LLC,  
its General Partner

By: /s/ Luke B. Evnin  
Name: Luke B. Evnin  
Title: Investment Manager

MPM ASSET MANAGEMENT INVESTORS 2002 BVII  
LLC

By: /s/ Luke B. Evnin  
Name: Luke B. Evnin  
Title: Investment Manager

MPM ASSET MANAGEMENT II LLC

By: /s/ Luke B. Evnin  
Name: Luke B. Evnin  
Title: Investment Manager



/s/ Ansbert Gadicke  
Ansbert Gadicke

/s/ Nicholas Galakatos  
Nicholas Galakatos

/s/ Kurt Wheeler  
Kurt Wheeler

**EXHIBITS**

/s/ Luke B. Evin  
Luke B. Evin

/s/ Michael Steinmetz  
Michael Steinmetz

A: Joint Filing Agreement